Diagnostic and prognostic value of PCA 3 score in patients with prostate tumors
DOI:
https://doi.org/10.26641/2307-5279.22.2.2018.135590Keywords:
prostate cancer, PCA 3 gene, biomarker, benign prostate hyperplasia, postmassage urine, PCA 3 scoreAbstract
Objectives: to determine the concentration of PCA3 gene mRNA in urine in patients with prostate tumors and estimate the diagnostic and prognostic value of it’s coefficient. Material and methods: 246 patients, 107 of which having prostate malignancies, 71 – BPH, and others without any prostate pathologies, have been recruited in cross-sectional, randomized studies carried out in the Ukrainian state institution of urology affiliated to the Academy of medical sciences of Ukraine. Determination of gene PCA 3 mRNA was performed by quantitative polymerase-chain reaction in real time (qRT-PCR) in conjunction with reverse transcription of primary product, thereafter the PCA 3 score for each patient being calculated. Results: PCA 3 mRNA contents in urinary sediments of expressed prostatic secretions of patients with PCa was shown to exceed significantly its values in patients with BPH and CHM–group. In turn, PCA 3 score which proved to be index of PCA 3 gene expression in the present in urinary sediments malignant epithelial cells, normalized by the expression of KLK 3 gene, was established to be endowed with prognostic properties appropriate for the application in laboratory diagnostics for prostate adenocarcinoma emerging prognosis. Meanwhile a said biomarker was ineffective in testing tumor aggressiveness and tumor clinical stage. Conclusion: The clinical investigation of PCA 3 score prognostic properties is proposed to be expanded by recruiting more patients with PCa that appears to be of great use for further elucidation of PCA 3 score general diagnostic potential.References
Bussemarkers M.J. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer / M.J. Bussemarkers, A. van Bokhoven, G.W. Verhaegh [et al.] // Cancer Res. – 1999. – Vol. 59(23). – P. 5975–5979.
Hessels D. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer / D. Hessels, J.M.T. Gunnewiek, I. van Oort [et al.] // Eur. Urol. – 2012. – Vol. 44. – P. 8–16.
Fradet Y. uPM3, a new molecular urine test for the detection of prostate cancer / Y. Fradet, F. Saad, A. Aprikian // Urol. – 2004. – Vol. 64. – P. 311–315.
Tinzl M. DD3PCA3 RNA analysis in urine – a new perspective for detecting prostate cancer / M. Tinzl, M. Marberger, S. Horvath [et al.] // Eur. Urol. – 2004. – Vol. 64. – P. 182–186.
Deras I.L. PCA3: a molecular urine assay for predicting prostate biopsy outcome / I.L. Deras, S. M. Aubin, A. Blasй // J. Urol. – 2008. – Vol. 179. – P. 1587–1592.
Haese A. Clinical utility of the PCA3 urine assay in European men schedules for repeat biopsy / A. Haense, A. de la Taille, H. van Poppel [et al] // Eur. Urol. – 2008. – Vol. 54. – P. 1081–1088.
Nakanishi H. PCA3 molecular urine assay correlated with prostate cancer tumor volume: implication in selecting candidates for active surveillance / H. Nakanishi, J. Groskopt, H. A. Fritsche [et al.] // J. Urol. – 2008. – Vol. 179. – P. 1804–1809.
Crawford E. D. Diagnostic performance of PCA3 to detect prostate cancer in man with increased prostate specific antigen: a prospective study of 1,962 cases / E. D. Crawford, K. O. Rove, E. J. Trabulsi [et al.] // J. Urol. – 2012. – Vol. 188. – P. 1726–1731.
Qu M. Current early diagnostic biomarkers of prostate cancer / M. Qu, Sh.-Ch. Ren, Y. Sun // Asian. J. Androl. – 2014. – Vol. 16. – P. 549–554.
Григоренко В.М. Біомаркери ранньої та диференційної діагностики раку передміхурової залози / В.М. Григоренко, Р.О. Данилець, М.В. Вікарчук [та ін.] // Клінічна хірургія. – 2017. – № 1. – С. 43–48.
Epstein J.I. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostate carcinoma / J.I. Epstein, W.C. Allsbrook, M.B. Amin [et al.] // Am. J. Surg. Pathol. – 2005. – Vol. 29, N 9. – P. 1228–1242.
Heidenreich A. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease / A. Heidenreich, J. Bellmunt, M. Bolla [et al.] // Europ. Urol. – 2011. – Vol. 59. – P. 61–71.
Ng C.F. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients / C.F. Ng, R. Yeung, P.K.F. Chiu [et al.] // Hong Kong Med. J. – 2012. – Vol. 18, N 6. – P. 459–465.
Altman D.G. Practical statistics for medical research / D.G. Altman. 1st ed. – Chapman and Hall: CRC, 1990. – 624 p.
van den Bergh R.C.N. Short-term outcomes of the prospective multicentre “Prostate cancer research International: Active surveillance” study / R.C.N. van den Bergh, H. Vasarainen, H.G. van der Poel [et al.] // BJU International. – 2009. – Vol. 105. – P. 956–962.
Roobol M.J.A framework for the identification of man at increased risk for prostate cancer / M.J. Roobol, F.H. Schroder, E.D. Crawford [et al.] // J. Urol. – 2009. – Vol. 182. – P. 2112–2122.
Ferro M. Prostate health index (Phi) and prostate cancer antigen 3 (PCA 3) significantly improve cancer detection at initial biopsy in a total PSA range of 2–10 ng/ml / M. Ferro, D. Bruzzese, S. Perdona [et al.] // PLoS ONE. – 2013. – Vol. 8(7). – P. 156–161.
Shappell S.B. Clinical use of urine PCA 3 mRNA testing / S.B. Shappell, L.S. Marks // Urology Times. – 2009. – Vol. 73(2). – P. 363–368.
Downloads
Published
Issue
Section
License
Стаття повинна мати візу керівника та офіційне направлення від установи, з якої виходить стаття (з круглою печаткою), і вказівкою, чи є стаття дисертаційною, а також у довільній формі на окремому аркуші - відомості про авторів (прізвище, ім’я, по батькові, посада, вчений ступінь, місце роботи, адреса, контактні телефони, E-mail).
Стаття повина бути підписана всіма авторами, які укладають з редакцією договір пропередачу авторських прав (заповнюється на кожного автора окремо з оригінальним підписом). За таких умов редакція має право на її публікацію та розміщення на сайті видавництва.
